These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 13678943)
1. A novel point-of-care enoxaparin monitor for use during percutaneous coronary intervention. Results of the Evaluating Enoxaparin Clotting Times (ELECT) Study. Moliterno DJ; Hermiller JB; Kereiakes DJ; Yow E; Applegate RJ; Braden GA; Dippel EJ; Furman MI; Grines CL; Kleiman NS; Levine GN; Mann T; Nair RN; Stine RA; Yacubov SJ; Tcheng JE; J Am Coll Cardiol; 2003 Sep; 42(6):1132-9. PubMed ID: 13678943 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of a novel point-of-care enoxaparin monitor with central laboratory anti-Xa levels. Saw J; Kereiakes DJ; Mahaffey KW; Applegate RJ; Braden GA; Brent BN; Brodie BR; Groce JB; Levine GN; Leya F; Moliterno DJ Thromb Res; 2003; 112(5-6):301-6. PubMed ID: 15041274 [TBL] [Abstract][Full Text] [Related]
3. Stable and optimal anticoagulation is achieved with a single dose of intravenous enoxaparin in patients undergoing percutaneous coronary intervention. Chen WH; Lau CP; Lau YK; Ng W; Lee PY; Yu CM; Ma E J Invasive Cardiol; 2002 Aug; 14(8):439-42. PubMed ID: 12147872 [TBL] [Abstract][Full Text] [Related]
4. Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial. Gibson CM; Murphy SA; Montalescot G; Morrow DA; Ardissino D; Cohen M; Gulba DC; Kracoff OH; Lewis BS; Roguin N; Antman EM; Braunwald E; J Am Coll Cardiol; 2007 Jun; 49(23):2238-46. PubMed ID: 17560287 [TBL] [Abstract][Full Text] [Related]
13. Enoxaparin anticoagulation monitoring in the catheterization laboratory using a new bedside test. Silvain J; Beygui F; Ankri A; Bellemain-Appaix A; Pena A; Barthelemy O; Cayla G; Gallois V; Galier S; Costagliola D; Collet JP; Montalescot G J Am Coll Cardiol; 2010 Feb; 55(7):617-25. PubMed ID: 20170785 [TBL] [Abstract][Full Text] [Related]
14. The use of intravenous enoxaparin in elective percutaneous coronary intervention in patients with renal impairment: results from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial. White HD; Gallo R; Cohen M; Steg PG; Aylward PE; Bode C; Steinhubl S; Montalescot G Am Heart J; 2009 Jan; 157(1):125-31. PubMed ID: 19081408 [TBL] [Abstract][Full Text] [Related]
15. Degree of anticoagulation after one subcutaneous and one subsequent intravenous booster dose of enoxaparin: implications for patients with acute coronary syndromes undergoing early percutaneous coronary intervention. Levine GN; Ferrando T J Thromb Thrombolysis; 2004 Jun; 17(3):167-71. PubMed ID: 15353913 [TBL] [Abstract][Full Text] [Related]
16. [The application of a 0.75 mg/kg intra-arterial dose of enoxaparin in coronary angiography and percutaneous coronary intervention]. Yuan F; Lü SZ; Chen YD; Song XT; Wang TS; Tian F Zhonghua Nei Ke Za Zhi; 2007 Mar; 46(3):200-3. PubMed ID: 17547800 [TBL] [Abstract][Full Text] [Related]
17. The use of a HEMOCHRON JR. HEMONOX point of care test in monitoring the anticoagulant effects of enoxaparin during interventional coronary procedures. El Rouby S; Cohen M; Gonzales A; Hoppensteadt D; Lee T; Zucker ML; Khalid K; Laduca FM; Fareed J J Thromb Thrombolysis; 2006 Apr; 21(2):137-45. PubMed ID: 16622609 [TBL] [Abstract][Full Text] [Related]
18. Enoxaparin in primary and facilitated percutaneous coronary intervention A formal prospective nonrandomized substudy of the FINESSE trial (Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events). Montalescot G; Ellis SG; de Belder MA; Janssens L; Katz O; Pluta W; Ecollan P; Tendera M; van Boven AJ; Widimsky P; Andersen HR; Betriu A; Armstrong P; Brodie BR; Herrmann HC; Neumann FJ; Effron MB; Lu J; Barnathan ES; Topol EJ; JACC Cardiovasc Interv; 2010 Feb; 3(2):203-12. PubMed ID: 20170878 [TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. White HD; Chew DP; Hoekstra JW; Miller CD; Pollack CV; Feit F; Lincoff AM; Bertrand M; Pocock S; Ware J; Ohman EM; Mehran R; Stone GW J Am Coll Cardiol; 2008 May; 51(18):1734-41. PubMed ID: 18452778 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]